BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$284.60 USD
+42.65 (17.63%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $285.16 +0.56 (0.20%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIO 284.60 +42.65(17.63%)
Will BIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 10th
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Other News for BIO
Bio-Rad (BIO) Stock Surges Over 15%
UBS Increases Price Target for Bio-Rad (BIO) to $325
RBC Capital Raises Price Target for Bio-Rad Laboratories (BIO) to $409 | BIO Stock News
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
BIO Crosses Above Key Moving Average Level